These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
55. [Use of hypothalamic phospholipid liposomes in patients with irritable bowel syndrome]. Aguglia E; Di Cataldo A; Sapienza S; Urbano D; Latteri F Clin Ter; 1985 May; 113(3):205-9. PubMed ID: 4017499 [No Abstract] [Full Text] [Related]
56. Some of the challenges in drug development for irritable bowel syndrome. Mayer EA Gut; 2001 May; 48(5):585-6. PubMed ID: 11302947 [No Abstract] [Full Text] [Related]
57. A review of irritable bowel syndrome and an update on therapeutic approaches. Bassett JT; Cash BD Expert Opin Pharmacother; 2008 May; 9(7):1129-43. PubMed ID: 18422471 [TBL] [Abstract][Full Text] [Related]
58. Re: Brandt et al.--An evidence-based approach to the management of irritable bowel syndrome in North America. Avigan M; Justice R; Mackey AC; Nair N Am J Gastroenterol; 2003 Sep; 98(9):2105-6. PubMed ID: 14499800 [No Abstract] [Full Text] [Related]
59. [Tegaserod in treatment of women with irritable bowel syndrome]. Munck LK; Ainsworth MA Ugeskr Laeger; 2007 Jun; 169(23):2190-2. PubMed ID: 17592683 [TBL] [Abstract][Full Text] [Related]
60. Patients with irritable bowel syndrome in primary care appear not to be heavy healthcare utilizers. Faresjö A; Grodzinsky E; Foldevi M; Johansson S; Wallander MA Aliment Pharmacol Ther; 2006 Mar; 23(6):807-14. PubMed ID: 16556183 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]